PharmaCyte Biotech reported continued losses for QQ2 2025, with net income of -1.46956 million and EBITDA of -1.10606 million on operating expenses of 1.10606 million and other expenses of 0.891018 million. Revenue for the quarter remains unavailable in the disclosed data, underscoring PharmaCyte’s early-stage, pre-commercial status. The company posted an operating cash burn of -1.054735 million and finished the period with a cash balance of 20.840056 million, reinforcing a net cash position that provides runway but limited near-term liquidity for commercial-scale activities.
Key Performance Indicators
Operating Income
Increasing
-1.11M
QoQ: 12.83% | YoY: 21.56%
Net Income
Decreasing
-1.47M
QoQ: -106.27% | YoY: -152.67%
EPS
Decreasing
-0.39
QoQ: -120.53% | YoY: -50.00%
Revenue Trend
Margin Analysis
Financial Highlights
- Revenue: N/A; Gross Profit: N/A; Operating Income: -1.10606 million with YoY increase of 21.56% and QoQ increase of 12.83% (interpreted as a narrowing loss versus the prior year quarter and improving sequentially). - Net Income: -1.46956 million; YoY: -152.67% (deterioration in bottom line vs year-ago period); QoQ: -106.27% (further deterioration versus prior quarter). - EPS: -0.39; YoY: -50.00%; QoQ: -120.53%. - Cash flow: Net cash used in operating activities -1.054735 million; Net cash from financing activities -10.740362 million; Cash at end of period 20.840056 million; Free cash flow: -1.054735 million. - Balance sheet: Total assets 55.098384 million; Total liabilities 11.647238 million; Total stockholders’ equity 43.451146 million; Cash and equivalents 20.840056 million; Intangible assets 1.549427 million; Long-term investments 24.855000 million; Current ratio 4.47; Net cash position -20.840056 million.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-1.11M
21.56%
12.83%
Net Income
-1.47M
-152.67%
-106.27%
EPS
-0.39
-50.00%
-120.53%
Key Financial Ratios
Return on Assets
Weak
-0.03%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.03%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
4.47
Current ratio indicates excellent liquidity and financial flexibility
P/E Ratio
Negative
-2.35x
Negative earnings make P/E ratio not meaningful
Price to Book
Undervalued
0.32x
Trading below book value, potential value opportunity or distressed
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.
PharmaCyte Biotech Inc (PMCB) QQ1 2026 Results Analysis – Revenue Gap, Large Non-Operating Charge, and Balance Sheet Position in a Cash-Rich Biotech...